Abstract:Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients.

Immunotherapy for Non-small Cell Lung Cancer: Current Agents and Potential Molecular Targets

Advances in T cells-based immunotherapy for non-small cell lung cancer

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Current status of immunotherapy for non-small cell lung cancer

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Advances of Immunotherapy for Non-small Cell Lung Cancer with Driver Gene Mutations

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

Shining Light on Advanced NSCLC in 2017: Combining Immune Checkpoint Inhibitors.

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

Immune Checkpoint Blockade As A Potential Therapeutic Target In Non-Small Cell Lung Cancer

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

Immunotherapy In Non-Small Cell Lung Cancer: The Clinical Impact Of Immune Response And Targeting

Recent Advances and Challenges of Immune Checkpoint Inhibitors in Immunotherapy of Non-Small Cell Lung Cancer

Emerging therapies for non-small cell lung cancer

Immunotherapy in Non-Small Cell Lung Cancer: the Clinical Impact of Immune Response and Targeting.

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application

Immunotherapy and Radiation Therapy for Non-Small Cell Lung Cancer—A Stimulating Partnership

Immune Checkpoint Inhibitors in Non-Small-cell Lung Cancer: Current Status and Future Directions

Emerging Evidence and Treatment Paradigm of Non-Small Cell Lung Cancer.